bài giảng nhôi máu cơ tim

!"#$%&'(%)*%+&%),-%
./0%1/0%!2(345%!26)%7(852%
!"#$%&#'($#$)*+#,#-)(#+.*#/#01#2"(#
-3&#45#6+7$#89*#:)*+#41&+#,#;(<&#'($#$)*+#;(<=#2>$#
!"#$%&'()#*+,"-+"#$%./0"'
9"852:%$5%;/%<$=:%>?-:)@85)3%1:@A::5%
% % %BCDE%85F%GEEEH%I%3:8JK↑%
'
'
'
'
'
'Cardiovascular disease
'
'
' 'Perinatal disease
Coronary heart
'disease
Stroke Other heart
'disease
-1 0 1 2 3 4 5
'Injuries
'
'
''Cancer
'
'
'' 'COPD
'
'
'' ' 'HIV

'
'
Other causes
?@&A>&=#6#@=#>BC#2DE:F#GHHIJIKLMNON,PKC#
12#34'
Deaths per 100,000 population
First beta-
blocker
developed
(Black)
GISSI
CASS
%L:)M$5:%$5%L:8@"K%=JN&%98JF$NO8K)(M8J%
L$K:8K:%$5%P:M8+N5%@N%/)$:5+Q)%RFO85):K%
'Year
'
'
600
'
'
500
400
'
'
300
'
'
200
'
'

100
0
1950 1960 1970 1980 1990 2000 2010 2020
'' '' '1961
'' '1954 Coronary
'' ''First care unit
Open-heart developed
'procedure (Julian)
''(Gibbon)
'1972
NHBPEP
'
' '''' '1979
' '''' Coronary
' 'angioplasty
' ''developed
' '''(Grüntzig)
''' '2007
'''Benefit of
cardiac resyn-
'chronization
'''therapy in
''heart failure
demonstrated
'''' '2002
'''Efficacy of
'drug-eluting
''''vs. bare-
metal stents
''determined

'
'
'
'
'''' '2002
''''ALLHAT
''' 1992
'SAVE
'
'
'
'
'
''' '1993
'Superiority of
primary PCI vs.
''fibrinolysis in
acute MI noted
''1985
'TIMI 1
'
'
'
'
'' ''1986
1983
'' '''and
'' 'ISIS-2
'
''1985

'NCEP
' ' '1980
'First implantable
cardioverter-defibrillator
' 'developed
(Mirowski)
' '1969
' ''First
description
'of CABG
(Favaloro)
'''1976
''''First
HMG CoA
reductase
'inhibitor
described
''(Endo)
''' ' '''' '1962
''' '1958
''Coronary
arteriography
'Developed
'''(Sones)
'
''' ' '''1961
''' ' ''''Risk
''' ' ''factors
''' ' 'defined
in early-onset

'MI described
'
'' ' '2009
'' 'Deep gene
''sequencing for
'responsiveness
to cardiovascular
drugs performed
''''''' '2009
''''Left-ventricular
'''assist device as
'destination therapy
''in advanced heart
''''''failure shown
'''''to be effective
'
'
'''''''2009
Genome wide
''association
2>Q@B#DR#>&S#!T>U&V>BS#DC#GHWGJIOOMXKYOI#
Foam
Cells
Fatty
Streak
Intermediate
Lesion
Atheroma
Fibrous
Plaque

Complicated
Lesion/Rupture
Endothelial Dysfunction
Smooth muscle
and collagen
From first decade From third decade From fourth decade
Growth mainly by lipid accumulation
Thrombosis,
hematoma
Adapted from Stary HC et al. Circulation 1995;92:1355-1374.
.$S5%@J$T5%)U8%&V52%?*%OW8%%
XY%@"Z52%&[)"%O\5"%
5(]$%^(V%+&%O\%"_(%^(V%
`"$%ab%@c)%52"d5%
!"_-%O$Y5%FN%"e$%)"f52%O\5"%),-%@[$%XN8%gh%
5/),2'6030*#37'
87*930"24:'
;.<='>$%%$0*'?04@$,#%'59"$44$0*4'A'568'
B5CD8E!>F
G'
8E!>F'
;.HI'"$%%$0*''
59"$44$0*4'@23'72#3'
J.KK'"$%%$0*''
59"$44$0*4'@23'72#3'
:L3$"#37'#*9'42/0*9#37'9$#+*0424.'G5M0),'J.<='"$%%$0*'D8E!>F'#*9'J.N='"$%%$0*'B5.'
?2#3,'O$42#42'#*9'8,30P2'8,#Q4Q/4'R'HJJ='B@9#,2.'6$3/)%#Q0*'HJJ=S';;<&NTR;=;.'
'Acute Coronary Syndromes
'
1.41 million hospital admissions for ACS in 2010

'
'
'
'
'
' '
'
'
'
0@>T=#Z(8@>8@#>&S#[=T\]@#[=>^8^*8#,#GHHWK#_`S>=@C#6(T*UB>^\&C#GHWKJWGLM@GN,@GLG#
.i%MY%&j$%&c)%!k9.%),-%l%XN8%gh%
• /@+#ab#@=#>BC#2#D&cB#E#:@S#GHWHJIOGMGWXXYOX#
.m%ON52%nE%52\3%
.m%ON52%nE%52\3%
6UA>V'W0X/'E30@0*$*'
E30@0*$*',Y*+'W0X/'PWZ*+'
dS>`=@S#AT\$#:(*+>@B#Z>4(@8#
Xe$%)"f52%okp%),-%`"]52%
)q%rN[5%/.%)"s5"%Ms5%
%%Xe$%)"f52%okp%),-%)q%
rN[5%/.%)"s5"%Ms5%
'?[$'/W\*+']^*W'6_@'A'5/),2'6030*#37'87*930"2'
8$*W'%`'
Ma*W'
Eb/'?0^*',0^*'
6_@'c*W''''
Eb/'UWZ*+'?0^*',0^*'
6_@'c*W'
d$a*'Q"'
8E'6We*W'%e*''

/f'gh*W'
V_,',Wij*+'8ECE'
Vk*W',W)j*+'W0X/''
UWZ*+'lm/'gh*W'
6Wn'g$o"''
4$*W'Wp/'
E30@0*$*'
9iq*+'c*W'
E30@0*$*'
H'%r*'s"'c*W'
LWs*',r*+'
D+)7'/q''
D+)7'/q'6#0' D+)7'/q'EW_@'
lt',3u'
d$v)',3h'Mw0',x*'W#7'6#*',W$a@'4y"'
6#*',W$a@'d>]C'
E$e)'4z$'W)7{,'
8E!>F' D8E!>F' B*4,#M%2'5*+$*#'
6W|*'
g0m*'
d$a*'Q"'
M#*'gr)'
d$a*'Q"'
/)f$''
D+)7'/q'}_,'6#0'
E30@0*$*'
9iq*+'c*W'
t"u5%MN[$%"e$%)"f52%O\5"%),-%%
dS>`=@S#AT\$#!>88>&S#@=#>BC#D0E#GHHPJ#GNM#WXLNYOOH#

o8(%52v)%`"]52%FN%"e$%)"f52%O\5"%),-% .JN-N5$5%@w52%`"]52%FN%"e$%)"f52%O\5"%),-%
!"#$%&'&()&'*(+&(',-' *('
•  ]>DE'/_@~'EO>E'
•  ]$e"'/q'Q"'/_@'
•  6q*',Y*+'W)7{,'m@~'"\/'g['*X*+'
•  Va*W'/q'Q"'90'4,3244'•WC/'E#P0AE4)M0€'
•  Va*W'/q'Q"'@Wk'g•$~'W‚@'ƒ#*'d>6'
•  8)7'Q"'/_@~'"\/'g['*X*+'
•  ?C/'d>6'/_@'•%„/',m/W~'"m)',…',W^*W€'
•  DWx$'"m)C,b/'"•/W'd>'@W†$'
•  6W_*',Wiq*+Cg…*+'9‡@'Q"'
!"#$%&'&()&'*(+&(',-' *('
•  ]$e"'/q'Q"~'"^*+'*+0^$'Q"'/_@'
•  6q*',Y*+'W)7{,'m@~'"\/'g['*X*+'
•  LWˆ'@W†$'/_@'W0X/'4)7'Q"'\'W)7{,'*X*+'
•  Va*W'/q'Q"'90'4,3244'•WC/'E#P0AE4)M0€'
•  8#)'/q*'*Wh@'*W#*W'W0X/'*Wh@'/W‡"'
•  6W_*',Wiq*+Cg…*+'9‡@'Q"~'4#)'gf,'}‰'*Wh@~'
,•0'*Wh@~'4f/'g$a*~'4$*W',W${,'/q'Q"'
•  ‰„/',W^*W'd>6~'Ma*W'ƒ#*'d>6~'Ma*W'Ld6E'
•  Eb/'"•/W'@W†$~'E5‰d>L'*X*+'
!"#$%&'&()&'*(+&('&"/01',-' *('
•  60',Wb,~'ƒ$e"~',3^0'*+iz/',WŠ/'()w*'
•  ‰0‹,'9•'9^7~',m',3^*+~'ƒ$e"',Œ$'"‡,~',)•'
•  ]$e"'@W{'()w*C@W†$~'/q*'W2*'
•  ]$e"'"^*+'@W†$~'EO>L~'EU>L'
•  Eb/'"•/W'@W†$'"•*~'E5‰d>L'*X*+'
•  6W_*',Wiq*+'*+Š/'
•  ]$e"'PWy@'4…*'4ij*~'+Ž7'•iq*+'4ij*'
•  E†*',Wiq*+'gf,'4f*+Cg•#'ga"'/†C*+Š/'

•  ?23@24'‘04,23'
!"#$%&'&()&'*(+&('&"/01',-' *('
•  8)7',W‡*'•/_@'W0X/'"•*€'
•  Va*W'*X*+'/r*'Wx$'4\/'•DU'W)7{,~'4)7'WZ'W_@€'
•  Va*W'%`'EU'/_@'•EV>D~'l?'9iy$'*Wa*€'
•  V’*+'*X*+'•w*W'Wi“*+'”KJ•'9$a*'c/W'9#€'
•  E$e)'/q'ƒs*'
•  D+['g[/',W)f/'•W0m',3h'%$a)'#93$#"7/$*~'<A
–)030)3#/$%~'W23/2@Q*~'*p/'3b*—€'
•  Va*W'%`'/q'90'ƒ$e"'W0X/',W0m$'W0m'
•  8)7'+$m@'
•  DW$˜"'M[,~'W2"0/W30"#,04$4~'4#3/0$904$4'
•  lq'/\*+'Mk'
EW${)'"m)'/q'Q"'9iy$'*[$'"•/'
•g#)',Wb,'*+Š/'/†'g$o*€&'
''
8E'/We*W'•)f*+',W0m*+'()#'
PWZ*+'P™"',W#7'g†$'š}8''
EW${)'"m)'/q'Q"'•)7e*',W^*W'
•/q*'L3$*›"2,#%~'WC/'E#P0,4)M0:€&'
''
8E'/We*W'%e*',W0m*+'()#CM_,'
,Wij*+'4„*+'E'
D>6E'8E'PWZ*+'/We*W'%e*'
''
8E'/We*W'•)f*+'W0X/'E's"~'PWZ*+'
/„'4„*+'š~'*Wi*+'/„'Mœ*+'/W\*+'
W0•$',t'/q'Q"'•"2*'Q"€''
D>6E'8E'/We*W'%e*'
''

8E'/We*W'%e*~'M%f/'*Wm*W',3m$''''''
"y$'•)_,'W$a*~',W#7'g†$'4„*+'E~'
•)_,'W$a*'4„*+'š'W0•$',t~'
Xe$%)"f52%O\5"%),-%@Js5%r$Y5%@u& %r#%
R\BSQ@Tc@TF#d?C#6B(&(*>B#DB@*=T\*>TS(\cT>`+eM#d#[($`B(f@S#d``T\>*+F#P=+#@SF#:\8QeF#g&*F#[=C#?\U(8#GHHOC#
h#'>]\=8UQ\#iQ<&+#*3#^$#S\#8=T@88j#cke#2:6'#$1#]+%&c#=l*#&c+m&#-:;#
9"(3T5%r[N%"
!8&%"
!W"
x%yE%@(z$" %{%yE%@(z$"
23'*(%&('4%&'i]+%&c#S1e#=+n=#=To(pQBq*#&+o&+#=To(j"
]HC]K" •'H.<'""" •'H.J'""" •';.<'"""
6W)7o*'g•0'PWm/" •';.J'"" '"
]K}C]I}" •';.J'"":'" •'J.<'"""
]='g{*']T" •'J.<'"""
23'*(%&('5#6&"'i]+%&c#S1e#=+n=#=To(pQBq*#&+o&+#=To(j"
]HC]K" •'J.<'"""
6W)7o*'g•0'PWm/" •'';.J'"""
."83%rz$%rN[5%/.%2|$%}%@"$S(%&'('
D[6pd66rpd0dpb0r#'>8]#r\T*@#
DUT#0@>T=#E#GHHPJ#GNMGXGXC'
O_)'W$a)'+z$'`'PWm/&'
•  8E'"y$'/We*W'•)f*+'•'J.<""'g$'*+#*+C/W{/W'•)f*+'“'H'/WCg•0'%$e*'Q{@'
•  E's"'4s)'•';.J'""'“'W#$'/W)7o*'g•0'%$e*'Q{@'/„'}C8'”';.J'
•  8E'/We*W'•)f*+',ž'];A]K'Ÿ'E'9iq*+'“'*+ij$'/„'M%0/'*Wm*W',3m$'
/q52%7%aY5"%M}'
9"(3T5%r[N%" .$s(%)"(~5"
31%#'*(#7&'*89':';(<1'*='>?%&'@'*(#$A&'B./'41%&',C;'D0'E'F' "
];'g{*']K" •'HJ"42/"
F~'FF~'#]‰~'#] ~']IA]N" •'KJ'"42/ '"

31%#'*(#7&'-G19':';(<1'*='>?%&'@'*(#$A&'B./'41%&',C;"
]HC]K" •'HJ'"42/'W0X/'9•*+'š8 '"
F~'FF~'#]‰~'#] ~']IA]N" •'KJ'"42/'Ÿ''•';'""'W0X/'9•*+'š8"
¡z$'`'}'M_,',Wij*+&'a#s#KH#$8@*#t#;Wp;G#u#ap[#s#W#]v$#89&c#'#Sw3&c#
=w3&c#x&c#$1#]+%&c#*9#Tq(#B\)&#Sy&#=TUez&"
D[6pd66rpd0dpb0r#'>8]#r\T*@C#DUT#0@>T=#E#GHHPJ#GNMGXGXC'
!2(3s5%5"u5%a,@%@"•€52%@'$%)v)%@Js5%r$Y5%@u&%r#%`"]52%FN%"e$%)"f52%O\5"%),-%
23'*(%&('4%&'*6'BH&('
•  LWk*W'ƒm/W',W_,',3m$'
•  V%f/'*Wm*W'E~'WC/'¢.L.¢~'Ld6E~'9^7',W_,'E'
•  Va*W'*Ws*'gŽ'gX,'"m7',•0'*Wh@'
•  Em$'/Š/'4y"'•g$o"'£'/We*W'%e*€'
23'*(%&('4%&'*='I1C&'BJ1'
•  ]$e"'/q'Q"~'"^*+'*+0^$'Q"'/_@'
•  DWx$'"m)'@W†$'
•  }f$'%0•*'g$a*'+$w$'•P#%$'"m)',Y*+€'
•  E†*',Wiq*+'EU'/_@'•EV>D~'l?'9iy$'*Wa*€'
2=&"'3')-'
•  V${*'g†$',WZ*+',Wij*+~'ƒu'9…'“'*¤'•/W)7o*'
g•0'Me*'@Ww$€~',3¥'2"~',W${)'*$e*—'
•  E${*',3$o*',Š'*W$e*'4#)'*Wx$'"m)'
•  Va*W'"•/W'ƒ^*W'"•*'c*W'
•  ]$e"'"^*+'*+0^$C/q'Q"'/_@~'Ma*W'/q'Q"'
•  V%f/'*Wm*W'ECL~'9^7',W_,',3m$~'WC/'¢.L.¢'
•  8#)'/q*'Q"'*#*W'W0X/',•0'*W$@'Q"'
•  }f$'%0•*'/W)7o*'W0m'W0X/'g$a*'+$w$''
23'*(%&('5#6&"'*6'BH&('
•  š}8'M_,',Wij*+'•‰VVV~'¢.L.¢~',•0'*Wh@€'
•  O^7',W_,',3m$~'@Wk'g•$'/q'Q"'
•  Va*W'"•/W'ƒ^*W'"•*'c*W'

3'*K/'?L'
•  V${*'g†$',WZ*+',Wij*+~'ƒu'9…',m$'/Š/'4y"'
•  }f$'%0•*'/W)7o*'W0m'W0X/'g$a*'+$w$'•ƒu'9…'
P#%$'"m)'/#0€'
•  E†*',Wiq*+',Wr*'P$*W'/_@'c*W'•EV>>D~'
l?>D€'
23'*(%&('5#6&"'*='>(K$'BJ1''
•  ]$e"'/qC"^*+'
*+0^$'Q"''
•  E5‰d>L'/_@'
•  }f$'%0•*'g$a*'+$w$'
•,Y*+'P#%$'"m)€'
•  ‰VVV~'¢.L.¢~',•0'
*Wh@',ž*+'%Œ/'
•  8#)'*Wh@'*W#*W~'4f/'
g$a*'
•  6q*'E?5~'*X*+'
•  D+['g[/',W)f/'
•9$+0•$*€'
•  8f/~'ƒ$e"',)•'
•  EY*+',WZ*+'PWu'
Before Infarct After Infarct
Lost
Muscle
Infarct
% Muscle
Remaining
100
%
50%

0%
Acute chest pain
Shortness of breath
ECG changes
Ischemia
Necrosis
AMI = Ischemia + Necrosis
M3(1C#'-N#'*O',-P9'
• F>5'
• 6W0%$*2'
3J&'>(QO&"'RG-'*O',-9'
• >70+%0M$*'
•  5VL'
• W4AE30@0*$*'
3J&'>(QO&"'*O',-9'
• E30@0*$*'
3S&"'"N&('>(T>'>?N19'
• D#,3$)32Q/'@2@Q92'•VDL€'
!"#$'*O'*(#&"',-' *(9'
• >L¦'
• 6}L'
'
L,(%,5%K$5"%"6)%@JN52%"e$%)"f52%O\5"%),-%
•  D>6E'%^'§*W',3•*+'W0•$',t',{'M^0'/q'
Q"'90',W${)'"m)'*)Z$'9i¨*+'P‹0'9^$'
•  D>6E'/„'4Š',Y*+'ƒ^CW0X/'+$w"'"#3P23'
4$*W'Wp/'/q'Q"'•E30@0*$*€',3e*'u,'*W_,'
TT•'Mm/W'@Ws*'ƒh~'P™"',W20'•';'7{)',f&'
–  d#)',Wb,'*+Š/'P$o)'"•/W'ƒ^*W'
–  EW#7'g†$'g$a*',s"'gx'•8E'/We*WS'

M%0/'*Wm*W',3m$'"y$S'4„*+'š'Ma*W'%`€'
–  Vœ*+'/W\*+'Wk*W'w*W',W${)'"m)'/q'
Q"'•3f$'%0•*'ƒ‡*'g[*+'ƒˆ*+€'
–  ?k*W'w*W'W)7{,'PWf$',30*+'d>]'
•/W…@'/Wp*'%p/'d>]S'"†',t',W$—€'
ob5"%52"•8%&j$%O‚%5"#$%&'(%)*%+&%
<N[$%@Jƒ%"e$%)"f52%O\5"%),-%Oj$%"K„.JN-N5$5%
0>$$#6b#@=#>B#C#DUT#0@>T=#E#iGHWWj#IG#iGIjM#GLLLYIHXK#
…m%@J†%"e$%)"f52%O\5"%),-%%
!k9.%)q%/.%)"s5"%Ms5%
Mortality %
*
'!#3%7'>03,#%$,7'}#,24'•H;AK<'9#74€'$*'
>#©03'}#*90"$›29'8E!>F',3$#%4&';TªN'A'HJJN'
GISSI-1
Control
'
n=5,852
ASSENT-4
'Prim PCI
'
' ' n=838
APEX-MI
'Prim PCI
'
''n=2,885
'GISSI-1
' 'SK
'
n=5,860

''ISIS-2
'''SK +
'Aspirin
n=4,292
GUSTO-1
'tPA
'
n=10,396
HORIZONS
' '-AMI
'n=3,340
?)7{,'PWf$'
U)M0'E'2,'#%.'£'5"'60%%'6#39$0%'
HJJ=S<J&TKKATKT.'
‰0‹,'ƒ’'"w*+'ƒ¤#'•q'
D\,'ƒ’'"w*+'ƒ¤#'•q'
X(3S@%`"Z$%@JN52%5"#$%&'(%)*%+&%),-%
t"•*52%)"u&%r$‚(%@Jb%@JN52%!k9.%),-%
[*+$(S=#:#@=#>BC#!:E#GHWGJIKKMQ${C@IXO#
<J•'
;J•'
KJ•'
3U'4V'>W'D/&"'
.$s(%K|$%"(3S@%
985%@"$Y-%@"‡%rˆ(%
•  M3(X1'"1K&'40'*O',-'Y'ZO',-'40'R['R6&"P%
„%W0•$',t'/q'Q"'Q{*',3$o*',W20',Wj$'+$#*#
•  d>]'/r*',WZ*+'9‰!Š%!XR!X%9‰!Š%.‹.%
•  |}*+#=+w~*#4•&c#&+€(#$oU#•Ue‚=#ƒ5&+#=„#
4\&c#41#^…&#Bw†&c#‡>#

•  UW|*',3iq*+'gm*W'+$m~'†*'gh*W',0^*',3•*+S'
@Wm,'W$a*'ƒ^'PWf*+'/W{'M${*'/W\*+'
1$Y5%-"'-%a85%rˆ(%
•  UWf*+'/W{'/m/'M${*'/W\*+'
•  V_,'g[*+'
•  EW“'0•7'
•  ¡$w"'g#)&'"03@W$*'
•  54@$3$*'%$v)'*•@'•KJJ"+€'
•  LH1;H'W0X/'/%0@$90+32%'%$v)'*•@'
•  8,#Q*',30*+'HI'+$j&'%$v)'/#0'
•  ?2@#3$*'W0X/'/Wf*+'gZ*+'PWm/'•M$ƒ#3$%)9$*€'
•  6W‚*'M2,#'+$#0'/w"')f*+'•*{)'PWZ*+'66d€'
•  «6>6'•i)'Qe*'! '+$w"S'¬HI'+$j'*{)'?5'PWZ*+',W_@€''
•  UWf*+'/W{',f,'gij*+'W)7{,'•$*4)%$*€''